Over 25 years of experience and expertise in clinical research in the US and China
Oversaw a 21,000-patient ‘megatrial’ for Lovenox (enoxaparin) resulted in its successful global registration
Built the Asia Pacific regional R&D function of 1,400 staff members encompassing Japan, reporting directly to Global R&D
M.D. from Nanjing Medical University in China, Ph.D. in Immunology and Biochemistry from the University of British Columbia in Canada, Internal Medicine Residency and postdoctoral fellowship at Washington University School of Medicine, certified physician in the U.S. by the Educational Commission for Foreign Medical Graduates.
A physician scientist and senior executive with 25+ year biomedical research and biopharmaceutical R&D experience in oncology, form discovery, translational medical to clinical development;
Served as SVP and Head of Clinical Development at BeiGene, built BeiGene’s clinical team and led clinical development of 4 oncology assets from PhI to pivotal trials including the first anti-PD-1 mAb originated in China；
Led research and development on over 10 oncology assets while serving as Oncology Medical Director in Covance(US), Senior Principle Scientist in cancer translational medicine in Pfizer(US) and Research Scientist in cancer genomics in Tularik/Amgen(US);
Ph.D. from UT Southwestern Medical Center; postdoctoral fellowship at Harvard University; M.D. from Hubei Medical College.
Over 20 years of experience in investment banks and biopharmaceutical companies;
Managing Director and business unit leader of Asia Pacific Healthcare equity research at Goldman Sachs (HK). Head of the Asian healthcare research team at Citigroup (HK), pharmaceutical industry research experience at Citigroup(US);
Over 5 years of experience in drug research and development gained at global biotech Amgen;
MBA from Cornell , MS from University of Toronto and Ontario Cancer Institute.
Over 20 years of experience in oncology global BD&L, strategic marketing, management and scientific research;
Executive Director and Global Lead, Oncology BD&L, Merck (MSD). Executive Director and Global Head of Life Cycle Strategy, Novartis Oncology;
Played a key role in the success of 9 global oncology brands, led world-wide oncology BD at Merck and successfully achieved 34 deals in immuno-oncology;
Ph.D. from Columbia, MBA from Cornell and BS from Nanjing University.
Over 20 years of experience in oncology research and early clinical trials. Holds multiple international patents in Immuno-oncology and Gene Therapy；
Director of Immuno-oncology Research at Merck. Associate Director, MedImmune (US). Principal Scientist, Biogen (US);
Oversaw Keytruda research projects and helped enrich Merck’s pipeline and expand Keytruda franchise;
Ph.D. from Ohio University, Post-doctoral Fellow and Instructor of Medicine in Harvard Medical School; Investigator Massachusetts General Hospital, BS from Nankai University.
Over 20 years of experience in global oncology development and scientific research;
Executive Director of Oncology Early Development at Merck(MSD) where he oversaw the development of 10+ oncology products from preclinical to proof-of-concept stage;
Leader of the Oncology Team of Excellence for Strategy in Therapeutic Area at Daiichi-Sankyo where he led Phase III trial for paxidartinib;
Faculty as Assistant Member at Memorial Sloan-Kettering Cancer Center and Assistant Professor at Weill Cornell Medical School;
M.D and Ph.D. in Biochemistry & Molecular Biology from the University of Southern California; fellowship in Medical Oncology at Memorial Sloan-Kettering Cancer Center and board-certified medical oncologist.
Life Science technology professional with over 20 years’ experience；
General Manager at BSK BIO of Simcere. Manager Principal Scientist at Roche(US). Senior Scientist at Biospecifics Technologics(US)；
One launched biologics, five launched Companion Diagnostics and eleven IND approval. Led team manufacture billion-dollar value products;
BS and PhD from China Pharmaceutical University, Post-doctoral from Mount Sinai School of Medicine; NMPA-appointed expert for Institute of Executive Development Training.
Over 25 years of experience gained in primary health care institutions, within the former China Food and Drug Administration (CFDA), and at medical device and internet companies;
Served as Chief Food Safety Officer at Alibaba Group’s Ele.me, and Deputy General Manager of Public Affairs at Shenzhen Mindray Biomedical Electronics Co., Ltd.;
Served at the CFDA as the Director of the Development Planning Department , the Deputy Director of the General Office, the Assistant Director of the Emergency Management Department, and the Deputy Inspector of the Food Safety Supervision Department;
Deputy Director of the Health Bureau of Fengtai District in Beijing, and has over 10 years of experience in the public health field;
Master’s degree in Public Health from Hebei Medical University, bachelor’s degree in Preventive Medicine from Capital Medical University. Selected by the Bureau of Foreign Expert Affairs for an education program at Duke University for Public Policy, and also by the U.S. Government for the Humphrey Scholars program in Public Health at Emory University.